Etanercept
- PDF / 169,080 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 34 Downloads / 169 Views
1 S
Various toxicities: 5 case reports In an analysis of 76 patients, who had early axial spondyloarthritis and participated in the ESTHER trial, five patients [ages and sexes not stated] were described, who developed lymphoma (1 patient), sarcoidosis (1 patient), demyelinating neurological disease (1 patient), elevated liver enzymes (1 patient) and recurrent minor infections (1 patient) during treatment with etanercept for early axial spondyloarthritis [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. All adverse events were possibly associated with etanercept. Hence, treatment with etanercept was stopped for all five patients. Proft F, et al. Long-term clinical outcome of anti-tnf treatment in patients with early axial spondyloarthritis: 10-year data of the etanercept vs. sulfasalazin in early axial spondyloarthritis trial. Annals of the Rheumatic Diseases 79 (Suppl.): 1625 (plus poster) abstr. 1491, Jun 2020. Available from: URL: https://ard.bmj.com/ 803516257 [abstract]
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
